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Host factors required for viral replication are ideal
drug targets because they are less likely than viral
proteins to mutate under drug-mediated selective
pressure. Although genome-wide screens have iden-
tified host proteins involved in influenza virus replica-
tion, limitedmechanistic understanding of how these
factors affect influenza has hindered potential drug
development. We conducted a systematic analysis
to identify and validate host factors that associate
with influenza virus proteins and affect viral replica-
tion. After identifying over 1,000 host factors that
coimmunoprecipitate with specific viral proteins,
we generated a network of virus-host protein interac-
tions based on the stage of the viral life cycle affected
upon host factor downregulation. Using compounds
that inhibit these host factors, we validated several
proteins, notably Golgi-specific brefeldin A-resis-
tant guanine nucleotide exchange factor 1 (GBF1)
and JAK1, as potential antiviral drug targets. Thus,
virus-host interactome screens are powerful strate-
gies to identify targetable host factors and guide
antiviral drug development.
INTRODUCTION
Viruses, which rely on host cellular functions to replicate, hijack
the host cell machinery and rewire it for their own needs. A
comprehensive understanding of host-virus interactions wouldCell Host &greatly improve our understanding of the viral life cycle and be
invaluable in identifying strategies to prevent or treat potentially
deadly virus infections.
Influenza viruses cause annual epidemics and recurring pan-
demics, which have claimedmillions of lives and had a consider-
able impact on public health and the global economy. Recent
sporadic human infections with avian viruses of the H5N1 and
H7N9 subtypes have raised concerns about the pandemic po-
tential of these viruses (Gao et al., 2013; Li et al., 2014; Webster
and Govorkova, 2006; Yen and Webster, 2009). Two antiviral
drugs (that inhibit the ion channel [M2] or neuraminidase [NA]
proteins) are available (Davies et al., 1964; Hayden, 2001), but
the emergence of drug-resistant viruses has become a serious
problem (Bright et al., 2005, 2006; Dawood et al., 2009; Nicoll
et al., 2008). Therefore, there is an urgent need to identify targets
for antiviral drugs.
In recent years, six genome-wide screens have identified a
total of 1,449 human genes (including 110 human orthologs of
Drosophila genes) with potential roles in the life cycle of influenza
virus (Brass et al., 2009; Hao et al., 2008; Karlas et al., 2010;
Ko¨nig et al., 2010; Shapira et al., 2009; Sui et al., 2009). Meta-an-
alyses revealed limited overlap among these studies (de Chas-
sey et al., 2012; Mehle and Doudna, 2010; Watanabe et al.,
2010). This limited overlap may be caused by differences in the
experimental conditions of the screens. Also, the experimental
methods used in the screens might be suboptimal to investigate
the whole life cycle of influenza viruses (e.g., using nonpermis-
sive cells for influenza virus infection and/or nonauthentic influ-
enza virus [i.e., recombinant viruses possessing reporter genes]).
Moreover, the criteria used to determine the candidate host fac-
tors likely differed among the screens, and each screen might
include a number of false positives. More importantly, most of
these studies validated only subsets of potential host interactionMicrobe 16, 795–805, December 10, 2014 ª2014 Elsevier Inc. 795
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Figure 1. Overview of a Systematic Study to
Elucidate the Physical and Functional Host-
Viral Interactions in Influenza Virus Replica-
tion and to Identify Antiviral Drugs
(A and B) Schematic diagram of the identification
of host proteins that coprecipitated with 11 influ-
enza A viral proteins and affected viral replication.
(A) Mass spectrometry analysis identified 1,292
host proteins that coimmunoprecipitated with one
or more of the 11 FLAG-tagged influenza viral
proteins. (B) To identify host factors that affect
virus replication, cells were transfected with
siRNAs targeted to each of the 1,292 candidate
host genes and were then infected with influenza
virus. Virus titers and cell viability were then
determined. We identified 323 host genes whose
mRNA levels were downregulated, while virus
titers were reduced by more than two log10 units
compared with a control (299 host factors) or
increased by more than one log10 unit (24 host
factors).
(C) To better understand the role of the identified
host factors, we performed mechanistic studies
assessing different steps in the viral life cycle for
our ‘‘top hits,’’ i.e., 91 host factors whose siRNA-
mediated downregulation reduced viral replication
in cultured cells by at least three log10 units while
retaining > 80% cell viability.
(D) To identify antiviral drugs for influenza virus, we
searched for drugs targeting the 299 host factors
identified here and selected 11 drugs for in vitro
testing. See also Figures S1–S4 and Tables S1,
S2, and S3.
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Host Factors Involved in Influenza Virus Life Cyclefactors, and only a few of the validated candidates were as-
sessed for their function(s) in the viral life cycle. We therefore
used authentic influenza virus and a human cell line permissive
for influenza virus replication to conduct a systematic analysis
of influenza viral host interaction partners, which was followed
by extensive validation studies and a systematic assessment
of the functional roles of these host proteins in influenza virus
replication. This information was then used to identify targets
for antiviral drugs.
RESULTS AND DISCUSSION
Identification of Host Proteins that Coprecipitate with
11 Viral Proteins of Influenza A Virus and Are Involved in
Viral Replication
We first attempted to establish a comprehensive map of viral-
host protein interactions in human embryonic kidney (HEK) 293
cells, which support influenza virus replication (Hatta et al.,796 Cell Host & Microbe 16, 795–805, December 10, 2014 ª2014 Elsevier Inc.2007; Le Ru et al., 2010). Eleven FLAG-
tagged viral proteins (i.e., PB2, PB1, PA,
HA, NP, NA, M1, M2, NS1, NS2, and
PB1-F2, which represent all of the viral
proteins with the exception of the recently
identified potential accessory factors)
of an influenza A virus (A/WSN/33,
H1N1 subtype; WSN) were individually
expressed in HEK293 cells and thenimmunoprecipitated with an anti-FLAG antibody. Mass spec-
trometry analyses of the coprecipitated proteins identified
1,292 host proteins in total: 388, 322, 304, 351, 574, 675, 659,
531, 113, 42, and 81 host proteins coprecipitated with the viral
PB2, PB1, PA, HA, NP, NA, M1, M2, NS1, NS2, and PB1-F2 pro-
teins, respectively (Figure 1 and Table S1; note that the data for
NS2 were reported previously [Gorai et al., 2012]).
The coprecipitated host proteins may be specific binding part-
ners of influenza viral proteins with essential or nonessential
functions in the viral life cycle. Alternatively, theymay be nonspe-
cific—that is, false positive—binding partners resulting from
experimental artifacts such as the overexpression of viral pro-
teins in our assay and/or the absence of other viral components.
Therefore, to identify host factors that are specifically involved in
virus replication, we transfected HEK293 cells with siRNAs tar-
geted to each of the 1,292 candidate host genes (two siRNAs
for each host gene were used, as shown in Table S2; AllStars
Negative Control siRNA [QIAGEN] was used as a negative
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Figure 2. Network of Host-Influenza Viral Protein Interactions
Interactions among the viral proteins and the 323 host factors identified here (gray and magenta circles) were visualized by using Cytoscape (http://cytoscape.
org/). ‘‘Top hits’’ (for a definition, see text and legend to Figure 1) are shown in magenta. Also shown are the steps in the viral life cycle affected by downregulation
of the respective host factor. The network image is fully zoomable on the monitor. See also Tables S2 and S5.
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and then harvested the culture supernatants for virus titration at
48 hr postinfection. Virus titers were determined by using plaque
assays, which are a well-established and reliable method of virus
titration in influenza virus research. In parallel, we examined the
cell viability of siRNA-transfectedHEK293 cells by using theCell-
Titer-Glo assay, which determines the number of viable cells in
culture by quantifying the ATP levels and thereby signaling the
presence of metabolically active cells (see also Experimental
Procedures). We identified 323 host genes whose mRNA levels
were downregulated, as confirmed by qRT-PCR, that reduced
virus titers by more than two log10 units (299 host factors) or
increased virus titers bymore than one log10 unit (24 host factors)
compared with the control siRNA (see Experimental Procedures,
Figure S1, and Table S2). Moreover, downregulation of these
host factors did not reduce cell viability bymore than 40% (Table
S2). For the set of 323 host factors that coimmunoprecipitated
with viral proteins and affected influenza virus replication, we
generated a network of virus-host protein interactions that may
have critical roles in influenza virus replication (Figure 2). Sixty-
three of these host factors had been identified previously (Brass
et al., 2009; Hao et al., 2008; Karlas et al., 2010; Ko¨nig et al.,
2010; Shapira et al., 2009; Sui et al., 2009) (Table S3 and
Figure S2). Gene ontology and pathway analyses revealed that
the host factors identified here are involved in various cellular
functions, including many ‘‘housekeeping’’ processes such as
transcription, translation, cell cycle, and mRNA splicing mecha-
nisms (Supplemental Information, Figure S3, and Table S4).
The Roles of the Identified Host Factors in the Influenza
Virus Life Cycle
Most of the previous genome-wide screens identified the
affected viral life cycle step(s) for only a limited number of the
host factors identified in their experiments (Brass et al., 2009;
Hao et al., 2008; Karlas et al., 2010; Ko¨nig et al., 2010; Shapira
et al., 2009; Sui et al., 2009). Because such information is essen-
tial for a better mechanistic understanding of the viral life cycle
and to identify drug targets, we performed mechanistic studies
for our ‘‘top hits,’’ namely the 91 host factors whose siRNA-
mediated downregulation reduced viral replication in cultured
cells by at least three log10 units while retaining > 80% cell
viability (Figures 1, 2, and 3 and Table S5). As described above,Cell Host &we confirmed that the siRNAs targeting the 91 ‘‘top hits’’
decreased mRNA levels by qRT-PCR.
First, we assessed whether siRNA-mediated downregulation
of the ‘‘top hits’’ affected cellular gene transcription and/or trans-
lation bymeasuring the expression levels of theRenilla luciferase
reporter protein expressed under the control of a cellular RNA
polymerase II promoter. We found that siRNAs targeting 28
host factors significantly reduced the activity ofRenilla luciferase
(expressed under the control of a cellular RNA polymerase II pro-
moter) by more than 80% (p value < 0.05; Figure 3, and Tables
S5A and S5B), suggesting that depletion of these host factors in-
hibited cellular transcription and/or translation, which indirectly
inhibited influenza virus replication. Nonetheless, some of these
factors may also have specific roles in the viral life cycle. For
example, downregulation of several host factors in this category
also affected the intracellular localization of influenza virus pro-
teins as determined by immunofluorescence studies that de-
tected the viral HA, NA, NP, and M1 proteins in siRNA-treated
and virus-infected cells (Figures 4 and S4 and Table S5A).
To test the role of the ‘‘top hits’’ in viral genome replication and
transcription, we measured the activity of the viral replication
complex (which comprises the PB2, PB1, PA, and NP proteins)
based on its ability to replicate a virus-like RNA encoding the
firefly luciferase reporter protein in a mini-replicon assay as
described previously (Octaviani et al., 2010). We identified nine
host factors (BUB3, CCDC56, CLTC, CYC1, NIBP, ZC3H15,
C14orf173, CTNNB1, and ANP32B) that are critical for viral
genome replication and transcription because their downregula-
tion significantly decreased the relative viral RNA polymerase ac-
tivity by more than 50% compared with a control (p value < 0.05;
Tables S5A and S5B; see also Figure 3 for an overview). None of
these factors affected host protein synthesis, suggesting a spe-
cific effect on viral replication. BUB3, a mitotic checkpoint pro-
tein, and CTNNB1, catenin (cadherin-associated protein) beta
1, were also detected in the genome-wide screens conducted
by Brass et al. (Brass et al., 2009), Shapira et al. (Shapira et al.,
2009), and Karlas et al. (Karlas et al., 2010) (Table S3A). CTNNB1
is part of a complex that forms adherens junctions and plays a
role in cytoskeleton formation. Several of the factors identified
here, including CTNNB1, share cellular interaction partners (Fig-
ure S5), suggesting that they may function in similar cellular pro-
cesses. With the exception of BUB3 and CLTC, the host factorsMicrobe 16, 795–805, December 10, 2014 ª2014 Elsevier Inc. 797
Figure 3. Effects of siRNA-Mediated Downregulation of the 91 ‘‘Top
Hits’’ on the Influenza Virus Life Cycle
A summary of the effects of siRNA-mediated downregulation of the 91 ‘‘top
hits’’ on influenza virus replication steps. The percentages indicate the relative
efficiency compared with the negative control and correspond to the values
presented in Table S5. For factors with a significant effect on the early steps in
the viral life cycle, polymerase activity, or VLP formation, we did not test the
efficiency of vRNA and NP virion incorporation; these factors are shown in gray
in the respective columns.
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798 Cell Host & Microbe 16, 795–805, December 10, 2014 ª2014 Elsidentified in the polymerase activity assay did not coimmunopre-
cipitate with components of the viral replication complex (Table
S1A), suggesting an indirect effect on viral replication. This
finding may have important implications for drug development
given that the inhibitory effects of drugs directed at these host
factors may not be overcome easily by ‘‘escape’’ mutations in
viral proteins.
To determine whether the ‘‘top hits’’ are involved in the early
steps of the viral life cycle, we next infected siRNA-treated cells
with a replication-incompetent PB2-knockout virus whose poly-
merase PB2-coding region was replaced with that of the Renilla
luciferase reporter protein, as described previously (Ozawa
et al., 2011) (see Experimental Procedures). Due to the lack of
a functional PB2 gene, reporter expression is indicative of virus
binding, internalization, and/or limited replication driven by the
polymerase complex associated with the viral RNA segments
of the infecting virions. Twenty-three host factors including
several proteasome components affected these early steps in
the viral life cycle. siRNAs targeting fourteen of these 23 host
factors reduced cellular transcription/replication, whereas
those targeting the remaining nine human genes (BAG3, BRD8,
CCDC135, DDX55, DPM3, EEF2, IGF2BP2, KRT14, and
S100A4) appeared to have influenza virus-specific effects (Fig-
ure 3 and Tables S5A and S5B). None of the siRNAs targeting
these nine factors reduced viral replication as assessed in
mini-replicon assays (see above; Tables S5A and S5B), suggest-
ing that they have important roles in an earlier step in the viral life
cycle such as virus binding, internalization, and/or transport of
viral ribonucleoprotein (vRNP) complexes to the nucleus (see
below).
Next, we attempted to determine whether the 91 ‘‘top hits’’ are
critical for processes late in the viral life cycle, such as virion for-
mation. To this end, we treated cells with siRNAs to the ‘‘top hits’’
and examined the effect on the formation of influenza virus-like
particles (VLPs) derived from the M1, HA, and NA proteins (see
Experimental Procedures). The efficiency of VLP production
was calculated as the amount of M1 and HA in VLPs in the super-
natant compared with the amount of M1 and HA in cell lysates.
After removing the host genes that have general effects on
cellular replication/transcription, we identified 15 host genes
(ASCC3L1, BRD8, C19orf43, DDX55, DKFZp564K142, DPM3,
EEF2, FAM73B, FLJ20303, GBF1, NCLN, C14orf173, XPO1,
LRPPRC, and RCN1) whose siRNA-mediated downregulation
decreased the average of VLP production by more than 50%
compared with the control, although there were no statistically
significant differences (Figure 3 and Tables S5A and S5C).
None of these factors was identified in previous genome-wide
screens (Brass et al., 2009; Hao et al., 2008; Karlas et al.,
2010; Ko¨nig et al., 2010; Shapira et al., 2009; Sui et al., 2009).
Four of these host factors (BRD8, DDX55, DPM3, and EEF2)evier Inc.
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Figure 4. Effects of Selected siRNAs Targeting the 91 ‘‘Top Hits’’ on
the Intracellular Localization of Viral Proteins in Infected Cells
(A–C) To examine whether the downregulation of the 91 ‘‘top hits’’ affects the
intracellular localization of the viral proteins in virus-infected cells, siRNA-
transfected HEK293 cells were infected with 200 pfu of WSN virus per well of a
24-well tissue culture plate, fixed at 12 hr postinfection, and then stained with
an anti-HA, anti-NA, anti-NP, or anti-M1 antibody. The intracellular localization
of HA (A), NA (B), and NP (C) is shown. None of the siRNAs affected M1
localization. See also Figure S4 and Table S5.
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Cell Host &also affected the early steps in the viral life cycle and may thus
play a role in the intracellular transport of viral proteins and/or
vRNP complexes, functions that are essential during the early
and late stages of infection. Hence, these host factors may be
interesting targets for drug development.
Among the 91 ‘‘top hits,’’ there were 35 host factors whose
siRNA-mediated downregulation did not affect the virus life cycle
steps assessed to this point. Therefore, we determined whether
depletion of these factors affected the incorporation efficiency of
vRNPs into progeny virions (see Experimental Procedures). The
vRNP incorporation efficiency was determined by dividing the
amount of viral RNA or NP protein in viruses harvested from
the culture supernatants by the amount of viral RNA and NP
in the cell lysates. The downregulation of 28 host factors
decreased the incorporation efficiency of vRNA and/or NP by
more than 50% compared with a control (Figure 3 and Table
S5D); these differences were statistically significant (p value <
0.05), with the exception of MYH10, whose p value was 0.06
(Table S5D). In addition, several of these 28 host factors share
common cellular interaction partners; for example, CIRBP and
HNRNPK interact with RBMX, an RNA-binding protein with roles
in RNA transcription and splicing (indicated with a green arrow in
Figure S5E, and Table S5J). Based on this information, future
studies could be directed at assessing the exact roles of CIRBP,
HNRNPK, and potentially RBMX, in the packaging of influenza
vRNPs.
Further evaluation of the host factors described above and
their cellular interaction partners revealed a group of cellular fac-
tors likely involved in the intracellular transport of influenza
vRNP. For example, SUMO2, a cellular protein involved in pro-
tein sumoylation and localization (indicated with a blue arrow in
Figures S5B, S5D, and S5E), interacts with seven different host
factors (BRD8, PSMD11, SF3B2 [Figures S5B and S5D],
NSUN2, SNRNP200 [Figure S5D], THOC2, and TRIM28 [Fig-
ure S5E]) whose downregulation affected early steps in the viral
life cycle, VLP formation, and/or vRNP packaging (Figures S5B,
S5D, and S5E and Tables S5E–S5J). This is consistent with a
previous study that suggested a role for sumoylation in the influ-
enza viral life cycle (Wu et al., 2011). Host factors like SUMO2
that affect several steps in the viral life cycle may therefore be
attractive targets for antiviral compounds.
Insights into Host Factors Involved in the Influenza Virus
Life Cycle
On the basis of the analyses in this study, influenza virus-host
protein interactions can be mapped to individual steps of the
influenza virus life cycle (Figure 5), as outlined below.
Influenza virus infection begins with attachment of the viral
hemagglutinin (HA) protein to a cell surface receptor, followed
by internalization of the virus into cells, facilitated by endocytosis
(Marsh and Helenius, 2006; Matlin et al., 1981; Rust et al., 2004;
Sieczkarski and Whittaker, 2002). HA mediates the fusion be-
tween the viral and endosomal membranes, leading to the
release of vRNPs into the cytoplasm (Stegmann et al., 1990).
vRNP complexes are then transported through the cytoplasm
to the nuclear core complex. We identified several host factors
involved in these early steps in the viral life cycle (Figure 3 and
Table S5), perhaps by facilitating intracellular transport of influ-
enza vRNPs, as discussed earlier. For example, BRD8 (alsoMicrobe 16, 795–805, December 10, 2014 ª2014 Elsevier Inc. 799
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Figure 5. Putative Roles of Identified Host Factors in the Influenza Virus Life Cycle
Influenza virus is internalized by receptor-mediated endocytosis. The viral ribonucleoprotein (vRNP) complexes containing the eight viral genomeRNAs (depicted
by orange bars) are transported into the nucleus where replication and transcription of the viral genome take place. vRNPs formed with newly synthesized viral
RNA, NP, and viral polymerase proteins are transported from the nucleus to the cytoplasm. HA and NA are processed posttranslationally during their transport
from the ER to the Golgi apparatus. In the late stage of the viral life cycle, virion components are transported to the plasma membrane and progeny viruses then
bud from the cells. The light orange boxes indicate individual steps of the influenza virus life cycle; the gray boxes indicate host cellular processes that are likely
involved. Host factors identified in this study are grouped according to the viral life cycle steps they affected; light green circles indicate host factors identified in
previous studies. Among the ‘‘known host factors,’’ only XPO1 (also known as CRM1) was identified in this study. See also Table S5.
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Host Factors Involved in Influenza Virus Life Cycleknown as SMAP or SMAP2) plays a role in intracellular vesicle
trafficking (Tanabe et al., 2006) and binds to M1, the viral matrix
protein, which is a major structural component of influenza
virions. The interaction of M1 with BRD8 may affect intracellular
vesicle trafficking and hence the transport of incoming and
newly synthesized virus components to and from the plasma
membrane.
The nuclear import of influenza vRNP is mediated by impor-
tins, which are part of the active import machinery of the host
cell nuclear pore complex (NPC) (Deng et al., 2006; Gabriel
et al., 2008; O’Neill et al., 1995; Resa-Infante et al., 2008; Taren-
deau et al., 2007, 2008; Wang et al., 1997). Once the vRNPs are
transported into the nucleus, the replication and transcription
of influenza virus genomic RNA is facilitated by the viral polymer-
ase subunits (PB1, PB2, and PA) and the nucleoprotein, NP (re-800 Cell Host & Microbe 16, 795–805, December 10, 2014 ª2014 Elsviewed in Engelhardt and Fodor, 2006; Palese, 2007). Here, we
identified several host factors that appear to be important for
influenza viral RNA replication (summarized in Figure 3). Influ-
enza virus also uses cellular machinery for nuclear export
of vRNP complexes. Consistent with previous studies (Boulo
et al., 2007; Elton et al., 2001; Neumann et al., 2000), we found
that downregulation of XPO1 (also known as CRM1) suppresses
vRNP nuclear export (Figure 4C). Moreover, our 91 ‘‘top hits’’
include five other host factors whose suppression caused NP
accumulation in the nucleus (Figure 4C), suggesting that these
factors are likely involved in the nuclear export of influenza
vRNPs.
In the late stage of the virus replication cycle, virion compo-
nents such as vRNPs, M1, and the viral envelope proteins (HA,
NA and M2) are transported to the plasma membrane whereevier Inc.
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Figure 6. Effects of Selected Drugs on Virus
Titers and Cell Viability in Virus-Infected
Cells
(A and B) HEK293 (A) or A549 (B) cells were in-
fected withWSN virus at anmoi of 0.001. One hour
later, cells were washed and incubated with me-
dium containing the indicated concentration of
golgicide A (A) and ruxolitinib (B). DMSO (final
concentration, 1%) was used as a control. Forty-
eight hours later, culture supernatants were
harvested for virus titration and cell viability was
determined by using CellTiter-Glo. Average and
standard deviation of three replicates are shown.
The p value was calculated with Welch’s t test
compared with a nontargeting siRNA control. To
control for the multiplicity effect, p values were
adjusted using Benjamini-Hochberg’s procedure,
keeping the false discovery ratio < 0.05. Asterisk
indicates that the adjusted p value is < 0.05. See
also Figure S6 and Table S6.
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Host Factors Involved in Influenza Virus Life Cycleprogeny virions bud (Nayak et al., 2004). Although relatively few
host factors are currently known to be involved in these steps,
here we identified several host factors with potential roles in
the late stages of infection (see also earlier discussion of a poten-
tial role for BRD8; Table S5). Brass et al. (2009) showed that
depletion of subunits of the COPI complex reduced HA expres-
sion levels on the cell surface, suggesting a role for the COPI
complex in the transport of influenza viral envelope proteins
(i.e., HA and NA) to the cell surface. In agreement with their find-
ings, we found that depletion of GBF1 (Golgi-specific brefeldin
A-resistant guanine nucleotide exchange factor 1), which associ-
ates with the COPI complex, reduced the efficiency of VLP for-
mation (Figure 3), supporting the importance of this pathway in
influenza virus replication.
Taken together, the mapping of virus-host protein interactions
to individual steps of the influenza virus life cycle provides a sys-
tematic understanding of the mechanism of virus replication that
can be further utilized to explore targets for antiviral therapy.
Exploration of Targets for Antiviral Therapy Based on
299Host FactorswhoseSuppressionReduced Influenza
Virus Replication
To identify targets for antiviral therapy, we queried the DrugBank
database (Wishart et al., 2006), IPA (Ingenuity), and the database
of pharmaceutical companies (Millipore, Sigma Aldrich, and Sell-
eck Chemicals) for chemicals that suppress the functions of the
299 host factors whose suppression reduced virus titers bymore
than two log10 units. We identified 61 drugs (including bortezo-
mib and colchicine, which are known to interfere with influenza
virus replication [Patterson et al., 1979; Widjaja et al., 2010]
and therefore could serve as positive controls) that inhibited 44
of the 299 host factors (Table S6A).
Of these 61 drugs, we chose 11 for further testing based on
their availability. To test the efficacy of these drugs on influenzaCell Host & Microbe 16, 795–805, Dvirus replication, we infected HEK293
and A549 (human lung epithelial) cells
with WSN virus, treated them with the
11 selected drugs (Table S6B), andmeasured virus titers 48 hr postinfection. Histone acetyltransfer-
ase inhibitor II (100 mM), genistein (100 mM), 2,3-Butanedione 2-
Monoxime (30 mM), and WP1130 (50 mM) reduced virus titers by
more than five log10 units in at least one of the cell lines tested,
but also markedly decreased cell viability (Figure S6). In accor-
dance with previous studies (Patterson et al., 1979; Widjaja
et al., 2010), bortezomib (0.2 mM) and colchicine (2.5 mM)
reduced virus titers by four log10 units and two log10 units,
respectively, in A549 cells without causing major cell toxicity
(Figure S6B). Interestingly, golgicide A (10 mM) and ruxolitinib
(30 mM), which were not previously known to interfere with influ-
enza virus replication, markedly decreased virus titers in at least
one of the cell lines tested. Ruxolitinib (30 mM) did not cause
notable cell toxicity, whereas golgicide A (10 mM) decreased
the viability of HEK293, but not that of A549 cells (Figure 6, Table
S6B, and Figure S6). Golgicide A inhibits the Golgi-specific bre-
feldin A-resistant guanine nucleotide exchange factor GBF1,
which coimmunoprecipitated with M2. siRNAs directed to
GBF1 decreased virus titers by more than five log10 units (Table
S2), altered the intracellular localization of HA andNA (Figures 4A
and 4B), and decreased the efficiency of VLP production (Fig-
ure 3), indicating the potential involvement of GBF1 in the trans-
port of viral surface proteins. More importantly, ruxolitinib
reduced virus titers by three log10 units at a concentration of
30 mM, which had no effect on cell viability (Figure 6). This com-
pound inhibits JAK1, a tyrosinekinase that coimmunoprecipitated
with several viral proteins (Table S2). siRNA-mediated downregu-
lationof JAK1reducedvirus titersbymore thanfive log10units (Ta-
ble S2), inhibited virion formation (Figure 7A), and decreased the
efficiency of vRNP incorporation into virions in virus-infected cells
(Figure 7B and Tables S5A and S5D). In addition, siRNAs to JAK1
reduced theefficiencyof VLP formation to57.7% (seeTableS5C),
which was slightly above our cutoff of 50%, and explains why
JAK1wasnot identifiedas a ‘‘hit’’ in our VLPassays. These resultsecember 10, 2014 ª2014 Elsevier Inc. 801
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Figure 7. Role of JAK1 in Influenza Virus Replication
(A) siRNA targeting JAK1 reduced the formation of virus particles from virus-
infected cells. HEK293 cells transfected with the indicated siRNAs were
infected with WSN virus at an moi of 5. At 12 hr postinfection, cells were
subjected to transmission electron microscopy.
(B) Depletion of JAK1 inhibited vRNP incorporation into virions. siRNA directed
at JAK1 reduced relative levels of NP and vRNA in virions released from
HEK293 cells infected with WSN virus. See also Table S5C.
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Host Factors Involved in Influenza Virus Life Cycledemonstrate that JAK1mayplayan important role in the late steps
of influenza virus replication cycle.
Given the known function of JAK1 in immune responses, its in-
hibition would have been expected to increase, rather than
decrease, virus titers. Several JAK1 inhibitors are approved or
are in advanced clinical testing for the treatment of myelofi-
brosis, rheumatoid arthritis, and psoriasis in humans (Cutolo
and Meroni, 2013; Pardanani et al., 2011; Quinta´s-Cardama
et al., 2011), demonstrating their therapeutic potential. Overall,802 Cell Host & Microbe 16, 795–805, December 10, 2014 ª2014 Elsthe identification of JAK1 as a previously unrecognized target
to control influenza virus infection underscores the power of
our approach, providing a proof-of-concept for virus-host inter-
actome screens to identify host factors that could be targets for
antiviral drugs.
In summary, we present a comprehensive study to better un-
derstand interactions between influenza viral and host proteins.
We used this information to identify drug targets and found that
inhibition of GBF1 and JAK1 (which had not been considered
targets for anti-influenza viral drugs) drastically reduced influ-
enza virus titers in cultured cells with no appreciable effect on
cell viability. These findings demonstrate that this comprehen-
sive experimental approach has considerable potential for iden-
tifying drug targets.
EXPERIMENTAL PROCEDURES
Cells and Viruses
HEK293 and A549 (human lung epithelial) cells were cultured in DMEM (Sigma-
Aldrich) supplemented with 10% FCS (10% FCS/DMEM) and antibiotics at
37C in 5% CO2. Madin–Darby canine kidney (MDCK) cells were cultured in
Eagle’s MEM (GIBCO) with 5% NCS at 37C in 5% CO2. Influenza A/WSN/
33 virus (WSN; H1N1) was generated by use of reverse genetics, as described
previously (Neumann et al., 1999) and propagated in MDCK cells. Virus was
titrated by plaque assay in MDCK cells (Tobita et al., 1975). The PB2-knockout
virus possessing the Renilla luciferase gene (PB2-KO/Rluc virus) was gener-
ated with pPolIPB2(120)Rluc(120) (encoding Renilla luciferase flanked by
120 N- and C-terminal nucleotides derived from the PB2 segment) and plas-
mids encoding the remaining seven viral RNA segments, and propagated
and titrated in MDCK cells stably expressing the PB2 protein as described
previously (Ozawa et al., 2011).
Plasmids
Plasmids expressing viral RNAs or proteins were generated as previously
described (Li et al., 2009). For coimmunoprecipitation analysis, the coding
regions of the viral PB2, PB1, PA, HA, NP, NA, M1, M2, NS1, NS2, and PB1-
F2 proteins were cloned into the expression vector pCAGGS/MCS (Niwa
et al., 1991) in-frame with a FLAG-tag sequence at either the 50 or 30 end.
Consequently, expression plasmids encoding N- or C-terminally FLAG-tagged
viral proteins were generated.
Antibodies
Mouse antibodies recognizing the FLAG epitope (F1804) or b-actin (clone
AC-74) were purchased from Sigma-Aldrich. Mouse anti-M1 antibody (WS-
27/52), mouse anti-HA antibody (WS3-54), and mouse anti-NA antibody
(WS5-29) were kindly provided by Dr. Emi Takashita (National Institute of Infec-
tious Diseases, Tokyo, Japan). Mouse anti-Aichi NP antibody (2S-347/3) and
rabbit anti-WSN virus antibody (R309) were available in our laboratory.
Pull-Down Assay and Mass Spectrometry
Pull-down assays with HEK293 cells individually expressing the 11 FLAG-
tagged viral proteins, followed by mass spectrometry, were performed as
described previously (Gorai et al., 2012) and in the Supplemental Experimental
Procedures.
siRNA Treatment
For each candidate host factor identified by mass spectrometric analysis, two
siRNAs were selected from a predesigned genome-wide human siRNA library
(FlexiTube siRNA; QIAGEN) (Table S2). AllStars Negative Control siRNA
(QIAGEN) was used as a negative control. The siRNA against the NP gene of
WSN virus (GGA UCU UAU UUC UUC GGA GUU) was purchased from
Sigma-Aldrich. HEK293 cells were transfected twice with 25 nM (final concen-
tration, 50 nM) of siRNA duplexes using RNAiMAX Reagent (Invitrogen). At
24 hr after the second transfection, cell viability was measured by using the
CellTiter-Glo assay system (Promega) according to the manufacturer’sevier Inc.
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transfected cells were infected with 50 plaque-forming units (pfu) of WSN
virus per well of a 24-well tissue culture plate at 24 hr after the second siRNA
transfection. Forty-eight hours postinfection, supernatants were harvested
and virus titers were determined by means of plaque assays in MDCK cells.
Quantitative Reverse Transcription-PCR
To confirm the downregulation of host genes by their respective target siRNAs,
quantitative reverse transcription-PCR (qRT-PCR) experiments were per-
formed. HEK293 cells, transfected twice with 25 nM of siRNA (final concentra-
tion, 50 nM), were lysed at 48 hr posttransfection, and total RNAwas extracted
by using the Maxwell 16 LEV simplyRNA Tissue Kit (Promega). Reverse
transcription was performed by using ReverTra Ace qPCR RT Master Mix
(TOYOBO, Osaka, Japan) or SuperScript III Reverse Transcriptase (Invitro-
gen). The synthesized cDNA was subjected to quantitative PCR with primers
specific for each gene by using the THUNDERBIRD SYBR qPCR Mix
(TOYOBO). The relative mRNA expression levels of each gene were calculated
by the DDCt method using b-actin as internal control. Primer sequences are
available upon request.
PB2-KO/Rluc Virus Assay
HEK293 cells were transfected twice with 25 nM of siRNA. At 24 hr after the
second transfection, cells were infected with a replication-incompetent PB2-
knockout WSN virus (PB2-KO/Rluc virus) that possesses a reporter gene en-
coding Renilla luciferase in place of the coding region of the polymerase PB2
protein. At 8 hr postinfection, cells were subjected to the Renilla Luciferase
Assay System (Promega). Luminescence was detected by use of the
GloMax-96 Microplate Luminometer (Promega). This virus lacks the capacity
to synthesize PB2; therefore, only limited replication can occur, which is
dependent on the PB2 protein associated with infecting vRNP complexes.
Immunofluorescence Microscopy
HEK293 cells transfected twice with 25 nM of the respective siRNA or AllStars
Negative Control siRNA were infected with 200 pfu of WSN virus per well of a
24-well tissue culture plate at 24 hr after the second siRNA transfection and
were then used in the immunofluorescence assay as described in the Supple-
mental Experimental Procedures.
Western Blotting
Cells or viruses were lysed with Tris-Glycine SDS sample buffer (Invitrogen),
heated for 10 min at 95C, and then immediately chilled on ice prior to SDS-
polyacrylamide gel electrophoresis (SDS-PAGE). SDS-PAGE was performed
on 4%–20% Mini-PROTEAN TGX gradient gels (Bio-Rad) for 30 min at 15–
20 mA, followed by western blotting as described in the Supplemental Exper-
imental Procedures.
VLP Formation Assay
HEK293 cells transfected twice with 25 nM siRNA were transfected with
pCAGGS plasmids expressing the viral proteins HA, NA, and M1 by using
TransIT293 transfection reagent (Mirus). At 48 hr after plasmid transfection,
cells were lysed with SDS Sample Buffer Solution (Wako) with 100 mM dithio-
threitol. The culture supernatant containing the released virus-like particles
(VLPs) was also harvested and centrifuged at 3,0003 g at 4C for 5 min to
remove cell debris. Supernatant was layered onto PBS-containing 30% (w/v)
sucrose in an ultracentrifuge tube. Ultracentrifugation was performed at
50,000 rpm at 4C for 1 hr in a SW55Ti Rotor. The pellet was lysed in SDS Sam-
ple Buffer Solution (Wako) with 100mMdithiothreitol and subjected to western
blotting as described above.
Mini-Replicon Assay
Mini-replicon assays to determine the activity of the influenza viral RNA
polymerase were performed as described previously (Octaviani et al., 2010).
HEK293 cells were transfected twice with 25 nM siRNA. At 24 hr after the sec-
ond transfection, cellswere transfectedwith pCAGGSplasmids expressing the
viral proteins PA, PB1, PB2, and NP, and with a plasmid expressing luciferase
from a virus-like RNA encoding firefly luciferase (pPolINP(0)luc2(0)) (Octaviani
et al., 2010). A plasmid expressing Renilla luciferase under the control of a
cellular RNA polymerase II promoter (i.e., the chicken b-actin promoter) wasCell Host &used as a transfection control. At 48 hr after plasmid transfection, cells were
subjected to a luciferase assay using the Dual-Glo Luciferase assay system
(Promega). Luminescence was detected with the GloMax-96 Microplate Lu-
minometer (Promega). The activity of the viral RNA polymerase was calculated
as the activity of the firefly luciferase normalized to that of theRenilla luciferase.
The efficiency of cellular gene transcription and/or translation was determined
based on the expression levels of the Renilla luciferase reporter protein.
vRNP Incorporation Assay
HEK293 cells transfected twice with 25 nM of the respective siRNA or AllStars
Negative Control siRNA were infected with WSN virus at a multiplicity of infec-
tion (moi) of 5. At 12 hr after infection, the medium containing the released
virions was centrifuged at 3,0003 g at 4C for 5 min to remove cell debris. Su-
pernatant was layered onto PBS containing 30% (w/v) sucrose in an ultracen-
trifuge tube. Ultracentrifugation was performed at 50,000 rpm and 4C for 1 hr
in a SW55Ti Rotor. Virus-containing pellets were homogenized in PBS and viral
RNAs were extracted by using the Maxwell 16 LEV simplyRNA Tissue Kit ac-
cording to the manufacturer’s instructions. To quantify viral RNA in cells and
supernatants, strand-specific real-time RT-PCR was performed as previously
described (Kawakami et al., 2011) with slight modification. Total RNA was
reverse transcribed with SuperScript III Reverse Transcriptase and influenza
gene-specific primers to which a 19 nucleotide ‘‘tag’’ sequence had been
added at the 50 end (e.g., vRNAtag_NP_1F; GGCCGTCATGGTGGCGAATAG
CAAAAGCAGGGTAGATAATCACTC). Quantitative PCR was carried out
using the THUNDERBIRD Probe qPCR Mix with primers specific for the
‘‘tag’’ (vRNAtag; GGCCGTCATGGTGGCGAAT) and the viral gene sequence
(WSN-NP_100R; GTTCTCCATCAGTCTCCATC), and with a probe labeled
with 6-FAM/ZEN/IBFQ (IDT, WSN-NP_46-70; ATGGCGACCAAAGGCACCA
AACGA T).
Effects of Antiviral Drugs on Influenza Virus Titers in Cultured Cells
To test the effects of the selected drugs on viral replication in vitro, HEK293 or
A549 cells were infected with WSN virus at an moi of 0.001. One hour later,
cells were washed and medium containing the indicated drug concentrations
was added. DMSO (final concentration, 1%) was used as a control. Forty-eight
hours later, culture supernatants were harvested for virus titration; cell viability
was determined in the mock-infected cells in the presence of drugs by using
CellTiter-Glo.
Electron Microscopy
HEK293 cells transfected twice with 25 nM of siRNA targeting JAK1 or AllStars
Negative Control siRNA were infected with WSN virus at an moi of 5. At 12 hr
after infection, the cells were processed for ultrathin section electron micro-
scopy as described previously (Noda et al., 2006). The samples were exam-
ined with a Tecnai F20 electron microscope (FEI).
Identification ofHost Proteins Involved in InfluenzaVirus Replication
For each set of siRNAs, the virus titers obtained from cells treated with gene-
specific siRNAs were compared with those obtained from cells treated with
AllStars Negative Control siRNA. siRNAs that decreased cell viability by more
than 40% relative to that of AllStars Negative Control siRNA-treated cells
were removed from further analysis. LOESS regression was applied to adjust
for the effect of cell viability on virus titers (FigureS1). The normalized virus titers
were fitted to a linear model and a two-sided, unpaired Student’s t test was
used to compare the mean virus titers in cells treated with gene-specific
siRNAs with those in cells treated with AllStars Negative Control siRNA. All
p values were Holm’s adjusted for multiple comparisons. Initially, we found
325 host genes whose siRNA-mediated downregulation reduced virus titers
by more than two log10 units (300 host factors) or increased virus titers by
more thanone log10 unit (25 host factors) comparedwith the control siRNA (Fig-
ure S1 and Table S2). However, the siRNAs targeting ARHGEF19 had opposite
effects on virus production, that is, one of the siRNAs targeting ARHGEF19
decreased virus titers, whereas the other siRNA increased virus titers
(Table S2); thus, ARHGEF19 was originally counted twice as having virus
titer-enhancing and -decreasing properties, respectively. After eliminating
ARHGEF19 from both lists, we arrived at a total of 323 genes involved in influ-
enza virus replication: 299 host genes whose suppression decreased virus
production and 24 host genes whose suppression increased virus production.Microbe 16, 795–805, December 10, 2014 ª2014 Elsevier Inc. 803
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WeperformedGene Ontology and pathway analysis using two web resources,
DAVID (Huang et al., 2009) and ConsensusPathBD (Kamburov et al., 2011).
The resultswere filtered to leave only entrieswithHochberg corrected p value <
0.01 in DAVID. We examined the ‘‘Biological Process’’ and ‘‘Cellular Compo-
nent’’ information and manually removed GO categories that were largely
overlapping as described in the Supplemental Experimental Procedures.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
six figures, and six tables and can be found with this article online at http://
dx.doi.org/10.1016/j.chom.2014.11.002.
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